Yashica Pharmaceuticals Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Yashica Pharmaceuticals Private Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $381.7K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Yashica Pharmaceuticals Private Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $381.7K Trade | TransData Nexus

Yashica Pharmaceuticals Private Limited

Indian Pharmaceutical Exporter · Antimalarial & Antiparasitic Specialist · $381.7K Total Trade · DGFT Verified

Yashica Pharmaceuticals Private Limited is an Indian pharmaceutical exporter with a total trade value of $381.7K across 3 products in 1 therapeutic categories. Based on 20 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Atovaquone ($189.7K), Proguanil ($109.0K), Mefloquine ($83.0K).

Yashica Pharmaceuticals Private Limited — Export Portfolio & Destination Treemap

Yashica Pharmaceuticals Private Limited pharmaceutical export portfolio — 3 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Yashica Pharmaceuticals Private Limited? — Company Overview & Market Position

Yashica Pharmaceuticals Private Limited is a privately held pharmaceutical company based in Kalyan West, Maharashtra, India. Established on November 15, 2007, the company specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Its Corporate Identification Number (CIN) is U24230MH2007PTC175913.

The company is led by directors Sanjay Khandu Totare and Vaishali Sanjay Totare, who have been associated with Yashica Pharmaceuticals since its inception. As of the latest available financial data, the company reported a total revenue of ₹2.00 crore, reflecting a 104.64% year-over-year growth. The net worth also saw a significant increase of 10.93%.

What Does Yashica Pharmaceuticals Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Atovaquone$189.7K 2Proguanil$109.0K

Product Portfolio — Top 3 by Export Value

Yashica Pharmaceuticals Private Limited exports 3 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Atovaquone	Antimalarial & Antiparasitic	$189.7K	5	0.0%	6
2	Proguanil	Antimalarial & Antiparasitic	$109.0K	7	0.0%	6
3	Mefloquine	Antimalarial & Antiparasitic	$83.0K	8	3.4%	3

Yashica Pharmaceuticals Private Limited exports 3 pharmaceutical products across 1 therapeutic categories with a total export value of $381.7K. The top category is Antimalarial & Antiparasitic (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Yashica Pharmaceuticals Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Yashica Pharmaceuticals operates manufacturing facilities in Maharashtra, India. In October 2024, the company received environmental clearance for the expansion of its Active Pharmaceutical Ingredients (APIs) and agrochemical products at Plot No. G 20, MIDC Lote Parshuram, Taluka Khed, District Ratnagiri, Maharashtra. This expansion is expected to enhance the company's production capacity and product range.

3Key Leadership

The leadership team at Yashica Pharmaceuticals comprises directors Sanjay Khandu Totare and Vaishali Sanjay Totare. Both have been instrumental in the company's growth and strategic direction since its establishment in 2007. Their combined experience and commitment have been pivotal in expanding the company's presence in the global pharmaceutical market.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Yashica Pharmaceuticals Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Yashica Pharmaceuticals has made significant strides in regulated markets, particularly in the United States, European Union, United Kingdom, Australia, and Japan. The company has pursued regulatory approvals for its finished pharmaceutical formulations, aligning with international standards to facilitate market access. While specific approval statuses are not detailed in the available data, the company's commitment to compliance with global regulatory requirements underscores its strategic focus on these markets.

2Emerging Markets

Yashica Pharmaceuticals has expanded its footprint in emerging markets across Africa, Latin America, Southeast Asia, and select Far East Asian countries. The company's products are available in over 35 countries, indicating a robust export strategy. The recent environmental clearance for the expansion of its manufacturing facility in Maharashtra is expected to bolster its capacity to meet the growing demand in these regions.

3Geographic Strategy

Yashica Pharmaceuticals demonstrates a diversified geographic strategy by exporting its products to more than 35 countries across continents, including South America, Europe, Africa, Southeast Asia, and parts of East Asia. This broad market presence mitigates concentration risk and positions the company to leverage growth opportunities in various regions. The recent expansion of its manufacturing facility in Maharashtra is a strategic move to support this diversification and enhance its global competitiveness.

Yashica Pharmaceuticals Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Yashica Pharmaceuticals' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not available in the provided data. However, the company's commitment to manufacturing high-quality pharmaceutical products suggests adherence to international standards, which is essential for FDA approvals. The recent environmental clearance for the expansion of its manufacturing facility indicates ongoing efforts to enhance production capabilities, potentially facilitating future regulatory approvals.

2WHO & EU GMP

Yashica Pharmaceuticals emphasizes compliance with international manufacturing standards, including Good Manufacturing Practices (GMP) as outlined by the World Health Organization (WHO) and the European Union (EU). The company's strategic partnerships with manufacturing associates possessing state-of-the-art facilities and processes in compliance with WHO, GMP, and FDA regulations underscore its commitment to quality. The recent environmental clearance for the expansion of its manufacturing facility in Maharashtra is expected to further enhance its compliance with these international standards.

CDSCO & Indian Regulatory

Yashica Pharmaceuticals Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Yashica Pharmaceuticals operates in the competitive pharmaceutical industry, focusing on finished pharmaceutical formulations such as tablets, capsules, syrups, and injections. While specific competitors are not identified in the available data, the company's emphasis on compliance with international standards, including WHO and GMP, positions it favorably in the market. The recent expansion of its manufacturing facility in Maharashtra is expected to enhance its production capacity, enabling it to better compete with other players in the industry.

2Key Differentiators

Yashica Pharmaceuticals' key differentiators include its commitment to manufacturing high-quality pharmaceutical products in compliance with international standards such as WHO and GMP. The company's strategic partnerships with manufacturing associates possessing state-of-the-art facilities and processes further enhance its product offerings. The recent environmental clearance for the expansion of its manufacturing facility in Maharashtra demonstrates the company's proactive approach to increasing production capacity and meeting global demand.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Yashica Pharmaceuticals Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Yashica Pharmaceuticals has demonstrated a strong track record in the pharmaceutical industry, with a focus on manufacturing and exporting finished pharmaceutical formulations. The company's export volume and consistency are supported by its presence in over 35 countries, indicating a reliable supply chain. The recent environmental clearance for the expansion of its manufacturing facility in Maharashtra reflects the company's commitment to enhancing its production capacity and meeting global demand.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm that the company's products are approved by the U.S. Food and Drug Administration. Verification can be done through the FDA's official website or by contacting the company directly.

WHO-GMP Certification: Ensure that the manufacturing facility complies with the World Health Organization's Good Manufacturing Practices. This can be verified by reviewing the company's certifications or contacting the WHO.

Frequently Asked Questions — Yashica Pharmaceuticals Private Limited

How many pharmaceutical products does Yashica Pharmaceuticals Private Limited export from India?

Yashica Pharmaceuticals Private Limited exports 3 pharmaceutical products across 1 therapeutic categories. The top exports are Atovaquone ($189.7K), Proguanil ($109.0K), Mefloquine ($83.0K). Total export value is $381.7K.

What is Yashica Pharmaceuticals Private Limited's total pharmaceutical export value?

Yashica Pharmaceuticals Private Limited's total pharmaceutical export value is $381.7K, based on 20 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Yashica Pharmaceuticals Private Limited cover?

Yashica Pharmaceuticals Private Limited exports across 1 therapeutic categories. The largest are Antimalarial & Antiparasitic (100.0%, 3 products).

Get Full Yashica Pharmaceuticals Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.